A trial looking at ruxolitinib to treat polycythaemia vera and essential thrombocythaemia (MAJIC)

Overview

Cancer types:

Blood cancers, Polycythaemia, Thrombocythaemia

Status:

Results

Phase:

Phase 2

Details

This trial looked at a drug called ruxolitinib to treat high risk polycythaemia vera (PV) and high risk essential thrombocythaemia (ET).

Polycythaemia vera and essential thrombocythaemia are . These are conditions in which the makes too many blood cells. In PV it is too many and in ET it is too many . These conditions are closely related to .

This trial closed in 2016. These results published in 2017 are for essential thrombocythemia. The trial team will publish the results of polycythaemia vera at a later date. When these results are published we will update this summary.

Recruitment start: 1 August 2012

Recruitment end: 31 July 2016